Market Overview

Canaccord Genuity Maintains Hold on Cardiome Pharma Corporation, Raises PT to $0.40

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for CRME

DateFirmActionFromTo
Mar 2015Mackie ResearchDowngradesSpeculative BuyHold
Nov 2014LaurentianInitiates Coverage onBuy
Jan 2014Canaccord GenuityDowngradesHold

View More Analyst Ratings for CRME
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (CRME)

Get Benzinga's Newsletters